Literature DB >> 10112585

The costs of treating hypertension--an analysis of different cut-off points.

M Johannesson1, L Borgquist, B Jönsson, L Råstam.   

Abstract

In this article the effects of different cut-off points for hypertension treatment are analysed, with respect to treatment costs. A theoretical blood pressure distribution is used to calculate the potential annual cost of treating all persons in Sweden above certain cut-off points for drug treatment. A lowering of the cut-off point from 105 mm Hg to 100 mm Hg diastolic blood pressure could potentially lead to an increase in annual costs of approximately 80m pounds. Further lowering from 100 to 95 mm Hg in turn could increase annual costs by about 110m pounds. The potential annual cost of treating all persons (roughly 1.6 million) with a diastolic blood pressure of greater than or equal to 95 mm Hg with drugs is calculated as being roughly 40 pounds per inhabitant in Sweden. The Swedish cut-off point for treatment (95 mm Hg) can be expected to lead to roughly 50 per cent higher treatment costs than the British cut-off point (100 mm Hg).

Entities:  

Mesh:

Year:  1991        PMID: 10112585     DOI: 10.1016/0168-8510(91)90095-f

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  14 in total

1.  Contemporary practice patterns in the management of newly diagnosed hypertension.

Authors:  F A McAlister; K K Teo; R Z Lewanczuk; G Wells; T J Montague
Journal:  CMAJ       Date:  1997-07-01       Impact factor: 8.262

Review 2.  Economic factors in the initiation of antihypertensive therapy.

Authors:  I Kawachi
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

Review 3.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

4.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

5.  Classification tree model of the personal economic burden of dementia care by related factors of both people with dementia and caregivers in Japan: a cross-sectional online survey.

Authors:  Takayo Nakabe; Noriko Sasaki; Hironori Uematsu; Susumu Kunisawa; Anders Wimo; Yuichi Imanaka
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

Review 6.  Pharmacoeconomic considerations in the management of hypertension.

Authors:  H Pardell; R Tresserras; P Armario; R Hernández del Rey
Journal:  Drugs       Date:  2000       Impact factor: 9.546

7.  Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials.

Authors:  Kristin Kahle-Wrobleski; Howard Fillit; Jonathan Kurlander; Catherine Reed; Mark Belger
Journal:  Eur J Health Econ       Date:  2014-11-20

8.  The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care.

Authors:  Anders Wimo; Linus Jönsson; Laura Fratiglioni; Per Olof Sandman; Anders Gustavsson; Anders Sköldunger; Lennarth Johansson
Journal:  Alzheimers Res Ther       Date:  2016-11-18       Impact factor: 6.982

9.  Stroke survivors' long-term QALY-weights in relation to their spouses' QALY-weights and informal support: a cross-sectional study.

Authors:  Josefine Persson; Lars-Åke Levin; Lukas Holmegaard; Petra Redfors; Katarina Jood; Christina Jern; Christian Blomstrand; Gunilla Forsberg-Wärleby
Journal:  Health Qual Life Outcomes       Date:  2017-07-25       Impact factor: 3.186

10.  The burden of Duchenne muscular dystrophy: an international, cross-sectional study.

Authors:  Erik Landfeldt; Peter Lindgren; Christopher F Bell; Claude Schmitt; Michela Guglieri; Volker Straub; Hanns Lochmüller; Katharine Bushby
Journal:  Neurology       Date:  2014-07-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.